The next hurdle in cancer immunotherapy: overcoming the non–T-cell–inflamed tumor microenvironment

TF Gajewski - Seminars in oncology, 2015 - Elsevier
A growing body of evidence suggests that a major subset of patients with advanced solid
tumors shows evidence for a T-cell–inflamed tumor microenvironment. This phenotype has
positive prognostic value for several types of early stage cancer, suggesting that the attempt
by the host to generate an anti-tumor immune response reflects a biologic process
associated with improved patient outcomes. In metastatic disease, the presence of this
phenotype appears to be associated with clinical response to several immunotherapies …